Location: United States
Total raised: $89M
Funding Rounds 1
| Date | Series | Amount | Investors |
| 29.03.2026 | Series B | $89M | Foresite C... |
Mentions in press and media 5
| Date | Title | Description |
| 30.03.2026 | Pinnacle Medicines Secures $89M Series B: Oral Peptides Advance Clinical Pipeline with AI Power | Pinnacle Medicines, a Doylestown, PA biotech, closed an oversubscribed $89 million Series B funding round. This significant capital injection accelerates its oral peptide therapeutics pipeline. The company targets immunology and cardiometab... |
| 29.03.2026 | Pinnacle Medicines: $89 Million Series B Raised For Oral Peptide Therapeutics Development | Pinnacle Medicines, a biotechnology company focused on oral peptide therapeutics, announced it has closed an oversubscribed $89 million Series B financing round to advance its pipeline into clinical trials. The round was co-led by LAV and F... |
| 26.03.2026 | Pinnacle Medicines Raises $89M in Series B Funding | Pinnacle Medicines, a Doylestown, PA-based biotechnology company developing oral peptide therapeutics, raised $89M in Series B funding. The round was led by LAV and Foresite Capital, with participation from Quan Capital, Hankang Capital, RA... |
| 26.03.2026 | OrbiMed-backed Pinnacle adds $89M series B to power oral peptide pipeline | Oral peptide specialist Pinnacle Medicines has secured an $89 million series B with backing from investors in the U.S. and China, bringing the company’s total fundraising haul to $134 million. OrbiMed, which has backed Pinnacle since its in... |
| - | Pinnacle Medicines | “Pinnacle Medicines -- Next Generation Peptide Therapeutics” |